Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Similar articles for PubMed (Select 22231610)

1.

Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials.

Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK.

Arch Intern Med. 2012 Feb 13;172(3):209-16. doi: 10.1001/archinternmed.2011.628. Epub 2012 Jan 9. Review.

PMID:
22231610
2.

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.

Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, Grove A, Gurung B, Morrow S, Clarke A.

Health Technol Assess. 2013 Sep;17(43):1-253. doi: 10.3310/hta17430. Review.

3.

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.

Berger JS, Krantz MJ, Kittelson JM, Hiatt WR.

JAMA. 2009 May 13;301(18):1909-19. doi: 10.1001/jama.2009.623.

PMID:
19436018
4.

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL.

JAMA. 2006 Jan 18;295(3):306-13. Erratum in: JAMA. 2006 May 3;295(17):2002.

PMID:
16418466
5.

Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.

Valentine N, Van de Laar FA, van Driel ML.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD005449. doi: 10.1002/14651858.CD005449.pub2. Review.

PMID:
23152231
6.
7.
8.

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A.

Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1.

9.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

10.

Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.

Bartolucci AA, Tendera M, Howard G.

Am J Cardiol. 2011 Jun 15;107(12):1796-801. doi: 10.1016/j.amjcard.2011.02.325. Epub 2011 Apr 8. Erratum in: Am J Cardiol. 2011 Aug 15;108(4):615.

PMID:
21481826
11.

Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.

De Schryver EL, Algra A, van Gijn J.

Cochrane Database Syst Rev. 2003;(1):CD001820. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD001820.

PMID:
12535415
12.

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW.

Lancet. 2012 Apr 28;379(9826):1602-12. doi: 10.1016/S0140-6736(11)61720-0. Epub 2012 Mar 21. Review.

PMID:
22440946
13.

Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

Keller TT, Squizzato A, Middeldorp S.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005158. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD005158.

PMID:
17636787
14.
15.

Nutritional support for liver disease.

Koretz RL, Avenell A, Lipman TO.

Cochrane Database Syst Rev. 2012 May 16;5:CD008344. doi: 10.1002/14651858.CD008344.pub2. Review.

PMID:
22592729
16.

Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.

Bowry AD, Brookhart MA, Choudhry NK.

Am J Cardiol. 2008 Apr 1;101(7):960-6. doi: 10.1016/j.amjcard.2007.11.057. Epub 2008 Feb 11. Review.

PMID:
18359315
17.

Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.

Butalia S, Leung AA, Ghali WA, Rabi DM.

Cardiovasc Diabetol. 2011 Apr 1;10:25. doi: 10.1186/1475-2840-10-25. Review.

18.

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.

Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Review.

19.

The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.

Hennekens CH, Schneider WR.

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. Review.

PMID:
18095910
20.

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.

Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J.

Diabetes Res Clin Pract. 2010 Feb;87(2):211-8. doi: 10.1016/j.diabres.2009.09.029. Epub 2009 Oct 23.

PMID:
19853947
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk